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Abstract
This study presents a broad overview of health issues and psychomotor development
of 100 children with Angelman syndrome (AS), seen at the ENCORE Expertise Center
for AS in Rotterdam, the Netherlands. We aimed to further delineate the phenotype
of AS, to evaluate the association of the phenotype with genotype and other deter-
minants such as epilepsy and to get insight in possible targets for intervention. We
confirmed the presence of a more severe phenotype in the 15q11.2-q13 deletion
subtype. Novel findings were an association of (early onset of) epilepsy with a nega-
tive effect on development, a high occurrence of nonconvulsive status epilepticus, a
high rate of crouch gait in the older children with risk of deterioration of mobility, a
relatively low occurrence of microcephaly, a higher mean weight for height in all
genetic subtypes with a significant higher mean in the nondeletion children, and a
high occurrence of hyperphagia across all genetic subtypes. Natural history data are
needed to design future trials. With this large clinical cohort with structured prospec-
tive and multidisciplinary follow-up, we provide unbiased data on AS to support fur-
ther intervention studies to optimize outcome and quality of life of children with AS
and their family.
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1 | INTRODUCTION
Angelman syndrome (AS) is a rare neurodevelopmental disorder char-
acterized by typical facial features, postnatal microcephaly, severe
developmental delay with lack of speech, movement disorders, char-
acteristic behavioral features, a high prevalence of epilepsy, and
sleeping and feeding problems. These features are part of the
Category A (100%), B (>80%), and C (20–80%) clinical criteria for AS
(Williams et al., 2006). AS is caused by mutations affecting the mater-
nally inherited UBE3A gene, most commonly due to a large deletion
of the chromosome 15q11.2-q13 region and in the other cases due to
paternal uniparental disomy (UPD), imprinting center defect (IC), or a
pathogenic variant of the maternal copy of the UBE3A gene (Beygo
et al., 2019; Kishino, Lalande, & Wagstaff, 1997; Matsuura et al.,
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1997; Williams et al., 2006). Among the children with a 15q11.2–q13
deletion, most have a 5.9 Mb (Class I) or a smaller 5.0 Mb (Class II)
deletion (Beygo et al., 2019; Mertz et al., 2013; Tan et al., 2011).
To improve care for AS patients and to acquire more knowledge
about the syndrome a multidisciplinary Expertise Center for AS was
established in 2010 at the Erasmus MC Sophia Children's Hospital in
Rotterdam, the Netherlands as part of the ENCORE Expertise Center
for Neurodevelopmental Disorders. The center was founded in close
collaboration with both the patient organization and patient advocacy
groups. Up until 2017, 100 children have visited the Expertise Center
for AS at least once.
Considering the potential upcoming treatments in AS, it is impor-
tant to get a more detailed view of all the health issues in AS, with a
focus on epilepsy and neurodevelopmental outcomes as these are
likely to be the target of future interventions (Beaudet & Meng, 2016;
Tan & Bird, 2016). Previous studies presented data of children with
AS on specific aspects like epilepsy, development, or growth and
mainly collected in a research setting (Gentile et al., 2010; Granild Bie
Mertz, Christensen, Vogel, Hertz, & Ostergaard, 2016; Mertz, Thaulov,
et al., 2014; Tan et al., 2011; Thibert et al., 2009; Thibert, Larson,
Hsieh, Raby, & Thiele, 2013). Our patients are taken care of by a mul-
tidisciplinary team of specialists, covering all aspects of AS. Based on
the incidence of AS (Mertz et al., 2013) and birth data in the Nether-
lands (Statistics Netherlands' database [Centraal Bureau voor de Sta-
tistiek], n.d.), our clinical cohort represents approximately 75% of all
children with AS in the Netherlands, forming a relatively unbiased
population. The aim of this study was to get a broad overview of
health issues and development of our patients and to analyze these
issues in relation to their genotype and other potential determinants
such as epilepsy. This allows us to further delineate the phenotype of
AS, identify opportunities to improve clinical care, better inform par-
ents and to establish natural history data for future intervention
studies.
2 | MATERIALS AND METHODS
This study presents prospectively collected data of the first 100 chil-
dren with AS who visited our Expertise Center between 2010 and
2017. One other patient was excluded from this cohort due to mosai-
cism of a deletion of the chromosome 15q11.2-q13 region and with a
far better phenotype (only a mild developmental delay) considered as
not comparable with the children with a true deletion. Clinical diagno-
sis was molecularly confirmed in all children by the referring clinicians
with the available genetic techniques at the time of diagnosis. Chil-
dren were diagnosed with combinations of methylation sensitive
digestion, methylation-specific PCR (MS-PCR), methylation-specific
multiplex ligation-dependent probe amplification (MS-MLPA), micro-
satellite marker analysis (MSA), fluorescent in situ hybridization
(FISH), MLPA analysis of copy number, Comparative Genomic Hybrid-
ization (CGH)- or Single Nucleotide Polymorphism (SNP)-array or sin-
gle UBE3A gene sequencing.
Clinical follow-up comprised annual visit of the pediatric neurolo-
gist and pediatrician. The first visit was attended by a clinical geneti-
cist as well. A standardized medical history was taken including a
parental questionnaire on epilepsy, sleep pattern, milestones, develop-
ment, behavior, nutrition, gastro-esophageal reflux (GER), defecation
pattern, and a physical exam including growth parameters was per-
formed at every visit. Other specialists were consulted or additional
examinations such as laboratory tests, radiological examinations, or
electroencephalography (EEG) were performed if needed. Cognitive
and behavioral assessment was performed by a psychologist and
child- and adolescent psychiatrist at the age of 3, 7, 11, and 15 years.
From 2014 onwards the program was expanded to include standard-
ized testing of language comprehension and (nonverbal) communica-
tion and observation of oral motor function by a speech therapist and
motor testing by a pediatric physical therapist at the age of 1, 2, 3, 4,
7, 11, and 15 years. Cognitive, motor, and receptive language devel-
opment was assessed using the Bayley Scales of Infant and Toddler
Development third edition (Bayley-III; Bayley, 2006). With absence of
speech the expressive scale of the Bayley-III did not contribute. A
mobility score adapted to the Gross Motor Function Classification
Scale(Palisano, Rosenbaum, Bartlett, & Livingston, 2008) was summa-
rized for analysis to three options: not walking (=1), walking with sup-
port (=2), or walking independently (=3). Early onset of epilepsy was
defined as onset before the age of 2 years. The effect of epilepsy is
considered most profound on brain development in the first 2 years
(Berg, Levy, & Testa, 2018).
All statistical analyses were performed using IBM SPSS version
24 (Corp, 2016). Unless stated otherwise, the children with a UPD, IC,
and a pathogenic variant of the UBE3A gene were grouped and
referred to as “nondeletion” group. Differences between groups were
calculated with independent t-tests or one-way ANOVA for normally
distributed continuous data. For categorical data a χ2 test was per-
formed; for groups of five or less patients a Fisher's Exact test. For
non-normally distributed data, a Wilcoxon signed rank test (or a Mann
Whitney U test when appropriate) was used. The mobility score, age
of independent walking and the raw scores of the Bayley-III were ana-
lyzed with correction for chronological age. We used the data of the
most recent visit to the age of 18 years and complete case analyses
were performed. All statistical tests were two-sided and p-values <.05
were considered statistically significant. This study was approved by
the Medical Ethics Committee of the Erasmus MC, the Netherlands
(MEC-2015-203). Written informed consent was formally waived, as
there was no patient burden or privacy concern.
3 | RESULTS
The data of 50 boys and 50 girls with molecularly confirmed AS are
presented in Table 1. In 2017, 77 children were in annual pediatric
follow-up, 11 had made the transition to the adult AS clinic at the age
of 19 years, and 12 children revisited our center less regularly. The
overall mean age at first visit was 5.7 years (SD = 4.8), but over time
this shifted toward mostly younger children. The mean age at first
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visit was 2.5 years (SD = 2.3) in 2016. There was no significant differ-
ence in age at most recent visit between the deletion and nondeletion
group.
3.1 | Genetics
The genetic diagnoses were a chromosomal 15q11.2-q13 deletion in
62%, UPD in 16%, IC in 4%, and a pathogenic variant of the UBE3A
gene in 18%.
Sex was equally divided for children with a deletion, UPD, and IC,
but there were twice as many females in the pathogenic variant of the
UBE3A gene group.
Children with a deletion were diagnosed at a significantly younger
age than the nondeletion children: mean age 22.5 versus
33.8 months (p < .05).
3.2 | Epilepsy and sleep
Eighty-two percent of the children were diagnosed with epilepsy, with
a significantly higher rate in the deletion group, as presented in
Table 2. The mean age of onset of epilepsy was 32 months (SD = 24.8)
with a significantly younger age of onset in the deletion group.
Most children (67%) had absence seizures. Tonic–clonic seizures
were reported in 43%, atonic seizures in 21%. An episode of a non-
convulsive status epilepticus (NCSE) occurred in 19% and a convulsive
status epilepticus in 5%. The occurrence of NCSE was significantly
higher in the deletion group. Of the 82 children with epilepsy, 38%
achieved seizure control on treatment with antiepileptic drugs (AED),
33% were still on, and 5% were successfully withdrawn from AED
treatment. Valproic acid was most commonly used as AED (65%),
followed by clobazam (33%), levetiracetam (25%), ethosuximide (15%),
and clonazepam (14%). Monotherapy was sufficient for 46% of the
children, usually this was valproic acid (61%). Valproic acid was dis-
continued in 20 children because of side effects (50%), lack of efficacy
(30%), and/or seizure remission of more than 2 years (25%). Reported
side effects were tremor, behavioral problems, drowsiness, nausea,
skin rash, and/ or elevated serum ammonia. Six percent of the children
with epilepsy were effectively treated with a low glycemic index diet
or ketogenic diet.
Sleep problems were reported by 91% of the parents, with diffi-
culty of settling in 57%, frequent waking in 87% and early waking in
59% of the children. There were no genotype differences. Medication
to improve sleep was used by 46% of the children. Melatonin was
used currently by 34% with variable doses and response and previ-
ously by 30% of the children. No association between sleep problems
and epilepsy was found (p = .16). Almost 20% of the parents reported
co-sleeping.
3.3 | Growth and other health issues
Mean head circumference was −1.4 SDS (SD = 1.0) at the most recent
measurement and was significantly lower in the deletion group
(Table 3 and Figure 1e). Microcephaly (≤−2.0 SDS) at the age of
2 years and older was seen in 24% of all children, twice as many
TABLE 1 General characteristics according to genotype
Deletion Nondeletion Total
N 62 38 100
UPD 16
IC 4
UBE3A 18
Sex (male/female) 34/28 16/22 50/50
UPD 7/9
IC 3/1
UBE3A 6/12
Age of diagnosis (mean
in months with SD)a
22.5 (23.7) 33.8 (21.2) 26.8 (23.2)
UPD 34.3 (28.9)
IC 39.8 (24.2)
UBE3A 32.1 (12.1)
Age at first visit (mean in
years with SD)
5.31 (5.1) 6.34 (4.2) 5.7 (4.8)
Age at most recent visit
(mean in years with
SD)
8.4 (5.4) 9.5 (5.4) 8.8 (5.3)
Abbreviations: IC, imprinting center defect; UPD, uniparental disomy.
aDeletion versus nondeletion p < .05.
TABLE 2 Epilepsy characteristics according to genotype
Deletion Nondeletion Total
N 62 38 100
Epilepsy,a n (% of genetic
subgroup)**
57 (92) 25 (66) 82
Age of first seizure, mean in
months (SD)b,*
24 (15.6) 52.9 (31.9) 32 (24.8)
Absence seizuresa, n (% of
genetic subgroup)
47 (76) 20 (53) 67
Tonic–clonic seizuresa, n (%
of genetic subgroup)
30 (48) 13 (34) 43
Atonic seizuresa, n (% of
genetic subgroup)
12 (19) 9 (24) 21
Nonconvulsive status
epilepticus, n (% of
genetic subgroup)*
16 (25) 3 (0.1) 19
Convulsive status
epilepticus, n (% of
genetic subgroup)
5 (0.1) 0 (0) 5
Epilepsy in remission with
or without AEDa, n (% of
genetic subgroup)
23 (40) 8 (32) 31
Abbreviation: AED, antiepileptic drugs.
aDefined as now or earlier.
bData from two deletion children missing.
*Deletion versus nondeletion p < .05.; **Deletion versus
nondeletion p < .01.
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children in the deletion group (30 vs. 15%) and absolutely seen in only
five children in the nondeletion group.
Mean height was −0.98 SDS (SD = 1.1) with a left shift of 1 SDS
of the normal distribution curve (Figure 1a). No effect of genotype
was observed. Being overweight (weight for height ≥1 SDS) was seen
in 18% and obesity (weight for height ≥2 SDS) in 20% of the children.
The mean weight for height in the total group was 0.67 SDS (SD = 1.4)
with a right shift of 1 SDS of the normal distribution curve (Figure 1b).
The mean weight for height was above 0 SDS in all separate genetic
subtype groups. Children in the nondeletion group had a significantly
higher mean weight for height than the children with a deletion
(Figure 1C). Within the nondeletion group children with a UPD or IC
(grouped) had a nominal significant higher weight for height than
those with a pathogenic variant of the UBE3A gene (p = .05;
Figure 1D). No sex difference was observed for weight for height.
Significantly more children with a deletion currently or previously
needed tube feeding. Thirty-two percent of the parents reported
hyperphagia, varying from no intrinsic limit in eating to searching for
food and eating nonfood items. There was no genotype association
with hyperphagia. Weight for height was significantly higher in the
children with hyperphagia (p < .001).
Gastro-esophageal reflux was reported significantly more often in
the deletion children. GER medication was currently used by 27% and
laxatives were used by 39% of the children. There was a trend toward
more constipation in the deletion children (p = .08). GER was seen in
all age groups.
Strabismus was seen in 40% and refraction errors were seen in
35% of the children. There was no significant effect of genotype. Sco-
liosis was seen in 18% of the children, of whom one needed surgery.
There was a trend toward a higher rate of scoliosis in the deletion
group (p = .10).
3.4 | Development
Children with a deletion had a significantly lower mobility score,
started walking independently later, and walked without support less
often than those with a nondeletion (Table 4 and Figure 2a). Age of
onset of independently walking was not significantly associated with
epilepsy or age of onset of epilepsy. Three children had lost their abil-
ity to walk independently. Crouch gait (i.e., walking in hip and knee
flexion and toeing out) was observed in 25% of the children. Crouch
gait was seen mostly in the older children, mean age of 13.4 years
(SD = 4.2), as shown in Figure 2b. No association with genotype, epi-
lepsy, weight for height, or scoliosis was found.
Figure 3 shows the Bayley-III raw scores of the gross motor, fine
motor, cognitive, and receptive language scales as a function of age.
The children with a deletion had significantly lower raw scores than
those with a nondeletion on both fine and gross motor, cognitive, and
receptive language development (all p < .05). The developmental quo-
tient (DQ, calculated as developmental age divided by chronological
age, times 100) was not different between deletion and nondeletion
for gross motor and fine motor development, but significantly differ-
ent for cognitive and receptive language development (Table 4).
TABLE 3 Growth, feeding problems, and other health issues
according to genotype
Deletion Non-deletion Total
N 62 38 100
UPD 16
IC 4
UBE3A 18
Head circumferencea,
mean in SDS (SD)
(n = 90)**
−1.67 (1.0) −1.08 (0.93) −1.44 (1.02)
Head circumference
≤−2 SDS at the
age of 2 years or
older, n (% of
genetic subgroup)
(n = 83)
15 (30) 5 (15) 20 (24)
Height, mean SDS
(SD) (n = 86)
−1.1 (1.1) −0.86 (1.1) −0.98 (1.1)
UPD −0.7 (1.4)
IC −1.0 (0.5)
UBE3A −0.9 (1.0)
Weight for height,
mean in SDS (SD)
(n = 86)*
0.35 (1.5) 1.15 (1.2) 0.67 (1.39)
UPD 1.5 (0.9)
IC 1.2 (0.3)
UBE3A 0.8 (1.4)
Tube feeding,b n (%
of genetic
subgroup)*
12 (19.4) 1 (2.6) 13
UPD 0
IC 0
UBE3A 1
Hyperphagia, n (% of
genetic subgroup)
16 (26) 16 (42) 32
UPD 7 (44)
IC 2 (50)
UBE3A 7 (39)
GERb, n (% of genetic
subgroup)**
39 (63) 11 (29) 50
Constipationb, n (%
of genetic
subgroup)
28 (45) 10 (26) 38
Strabismus, n (% of
genetic subgroup)
27 (44) 13 (34) 40
Refractive error, n (%
of genetic
subgroup)
24 (39) 11 (29) 35
Scoliosis, n (% of
genetic subgroup)
14 (23) 4 (10) 18
Abbreviation: GER, gastro-esophageal reflux.
aAt most recent measurement.
bDefined as now or earlier.
*Deletion versus nondeletion p < .05.; **Deletion versus
nondeletion p < .01.
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Children with epilepsy had a significantly lower DQ for both
gross and fine motor development (both p < .01) and cognitive and
receptive language development (both p < 0.05), as well as signifi-
cantly lower raw scores on gross motor, cognitive, and receptive
language development than those without epilepsy (all p < .05). A
trend was found toward lower raw scores for fine motor develop-
ment in the group with epilepsy (p = .06). Children with an epilepsy
onset before 2 years of age obtained significantly lower raw scores
for both gross and fine motor development than children with an
onset after 2 years of age (both p < .001). A similar association was
F IGURE 1 Growth parameters. (a) Mean height, (b) Mean weight for height, (c) Mean weight for height deletion versus nondeletion, (d) Mean
weight for height UPD-IC versus UBE3A-mutation, (e) Mean head circumference at most recent measurement. Dashed line indicates 0 SDS in
(a)–(d) and indicates −2 SDS as demarcation of microcephaly in (e). IC, imprinting center defect; UPD, uniparental disomy
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found for cognitive and receptive language raw scores
(both p < .01).
4 | DISCUSSION
This study presents a broad overview of health issues and develop-
ment and its associations with genotype and epilepsy of the first
100 children with AS seen at our Expertise Center for AS. This is the
largest clinical cohort described thus far. Our data confirm the distri-
bution of the genetic subtypes, the overall clinical presentation and
the presence of a more severe phenotype in the 15q11.2-q13 dele-
tion subtype (Clayton-Smith & Laan, 2003; Luk & Lo, 2016; Mertz
et al., 2013; Shaaya, Grocott, Laing, & Thibert, 2016; Tan et al., 2011).
Novel findings are a negative association of epilepsy and an earlier
age at onset of epilepsy on development, a high occurrence of NCSE,
crouch gait in the older children, a relatively low occurrence of micro-
cephaly, a higher mean weight for height in all genetic subtypes with a
significant higher mean in the nondeletion children, and a high occur-
rence of hyperphagia in all genetic subtypes.
4.1 | Genetics
Overall, the distribution of the underlying genetic causes in our AS
cohort is comparable to AS cohorts as reported for the United States,
Denmark, and Hong Kong, with chromosomal 15q11.2-q13 deletion
being the most common cause and an IC abnormality showing the
lowest prevalence (Clayton-Smith & Laan, 2003; Luk & Lo, 2016;
Mertz et al., 2013; Shaaya et al., 2016; Tan et al., 2011). In our cohort,
the mean age of diagnosis was significantly earlier in children with a
deletion than in children with a nondeletion, similar to other cohorts
(Mertz et al., 2013; Tan et al., 2011). This may reflect both the more
severe phenotype and the current availability of micro-array as a first
genetic tool in the diagnostic work-up of children with a developmen-
tal delay. Age of diagnosis for UPD and pathogenic variant of the
UBE3A gene was about a year younger in our cohort compared to
children diagnosed between 1991 and 2009 in Denmark (Mertz et al.,
TABLE 4 Mobility and motor, cognitive and language
development according to genotype
Deletion Nondeletion Total
N 62 38 100
Mobility score mean
(SD) (n = 38)**
1.87 (0.63) 2.67 (0.62) 2.29 (0.76)
Independent walking, n
(% of genetic
subgroup)***
25 (40) 30 (79) 55
Age of independent
walking (mean in
months and SD)***
57.9 (29.5) 41.1 (16.1) 48.9 (25.2)
Nonambulatory at age
≥4 years, n (% of
genetic subgroup)***
24 (39) 2 (0.05) 26
Loss of walking 0 3 3
Crouch gait, n (% of
genetic subgroup)
15 (24) 10 (26) 25
Bayley GM DQ (SD)
(n = 67)
16.4 (9.9) 19.9 (12.2) 17.6 (11.2)
Bayley FM DQ (SD)
(n = 66)
16.7 (13.0) 23.01 (12.98) 19.0 (13.6)
Bayley cognitive DQ
(SD) (n = 48)*
15.6 (8.3) 23.9 (14.5) 18.0 (11.6)
Bayley receptive
language DQ (SD)
(n = 41)**
14.8 (9.4) 26.9 (14.97) 20.6 (13.5)
Abbreviations: Bayley, Bayley scales of infant and toddler development;
DQ, developmental quotient; FM, fine motor; GM, gross motor.
*Deletion versus nondeletion p < .05.; **Deletion versus nondeletion
p < .01.; ***Deletion versus nondeletion p < .001.
F IGURE 2 Mobility parameters. (a) Mobility score versus genotype, (b) Crouch gait
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2013). This may reflect growing awareness of AS since a methylation
test and UBE3A gene sequencing test are performed only upon a
strong clinical suspicion of AS.
4.2 | Epilepsy
Up to 90% of the children with AS develop epilepsy and children with
a deletion have a higher risk as well as an earlier onset of epilepsy, as
was also confirmed in our cohort (Conant, Thibert, & Thiele, 2009;
Granild Bie Mertz et al., 2016; Lossie et al., 2001; Pelc, Boyd,
Cheron, & Dan, 2008; Tan et al., 2011; Thibert et al., 2009, 2013). A
more severe epilepsy phenotype is thought to be associated with the
involvement of the GABA-A receptor subunit cluster, which is part of
the 15q11.2-q13 locus. The occurrence of absence seizures and NCSE
in our cohort is high, as was also reported by Worden, Grocott,
Tourjee, Chan, and Thibert (2018). Early recognition of NCSE is impor-
tant, since we often observed a delay of days or weeks in the correct
diagnosis and a long time to recover to the pre-NCSE level of func-
tioning. We recommend educating the parents about the signs of
NCSE and to have prompt EEG confirmation in case of NCSE
suspicion to start treatment as early as possible. Symptoms of NCSE
that were seen in our cohort were lowering of consciousness where
patients were still responsive to stimuli, however unusually slow. Also
loss of already acquired milestones, less interest in food, increased
drooling, and episodes of staring were seen. If children regularly have
tonic–clonic or atonic seizures, the frequency of these seizures was
much lower during NCSE.
In our study 46% of the patients achieved seizure control using a
single AED, which was valproic acid in two-third of the cases. The
majority tolerated valproic acid well, in contrast to recent data from
Boston, where only 8% remained on valproic acid because of side
effects (Shaaya et al., 2016). In Denmark and Boston benzodiazepines
and levetiracetam, respectively, are prescribed as monotherapy most
commonly, which highlights local differences in AED treatment prefer-
ences (Granild Bie Mertz et al., 2016; Shaaya et al., 2016).
4.3 | Development
Gross and fine motor, cognitive, and receptive language Bayley-III raw
scores, and cognitive and receptive language DQ were significantly
F IGURE 3 Developmental parameters. (a) Bayley fine motor raw scores versus age, (b) Bayley gros motor raw scores versus age, (c) Bayley
cognitive raw scores versus age, (d) Bayley receptive language raw scores versus age
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lower in the children with a deletion compared to the nondeletion group,
as was published previously (Gentile et al., 2010; Mertz, Thaulov, et al.,
2014). Scores for both motor skills and cognitive and language develop-
ment were also significantly negatively associated with (early onset of)
epilepsy. This association has not been reported before. One small study
(n = 11) did not find an association between epileptic activity and devel-
opmental milestones (Ohtsuka et al., 2005). The question is whether
(early onset of) epilepsy is a direct cause of more severe developmental
delay (e.g., by interfering with brain development) or whether both epi-
lepsy and more severe developmental delay share a common neuropath-
ological etiology. It is unsure whether early or more aggressive
treatment of epilepsy in AS contributes to a better outcome, although
this has been shown in other syndromes (Curatolo et al., 2018).
The mean age of onset of independent walking and associated
genotype difference is comparable to earlier findings (Lossie et al.,
2001). Possible factors in the delay or failure of independent walking
can be instability due to tremor, abnormal muscle tone, balance prob-
lems, epilepsy, and/or visual problems. To our knowledge, the high
rate of crouch gait in the older children has not been reported earlier.
We did not find an association with sex, genotype, weight for height,
nor scoliosis. Lack of muscle strength, abnormal muscle tone, and/or
peripheral neuropathy could explain this gait problem. Further
research is necessary to gain more insight in the underlying mecha-
nisms of gait problems to seek for ways to prevent or delay crouch
gait since it can contribute to deterioration of mobility.
Visual problems were found in 40% of our children, as reported
before (Micheletti et al., 2016; Michieletto, Bonanni, & Pensiero,
2011). Visual function is highly important in mobility, motor and cog-
nitive development, and communication, so standard periodic screen-
ing is recommended.
4.4 | Sleep
The high prevalence of sleep problems in AS was confirmed in our
cohort and observed for all genotypes (Conant et al., 2009; Spruyt,
Braam, & Curfs, 2018; Thibert et al., 2013). Frequent waking occurred
most frequently (87%) in our cohort, problems in settling less fre-
quently than previously reported (Conant et al., 2009; Spruyt et al.,
2018; Thibert et al., 2013). Possibly less problems in settling are due
to the high use of melatonin (in the Netherlands freely available).
Whether epilepsy and/or AED cause sleep problems and/or whether
sleep deficit increases seizure susceptibility remains uncertain. The
earlier reported association between sleeping problems and epilepsy
could not be confirmed (Conant et al., 2009). Both biological and
behavioral factors may influence sleep in AS. In mouse models a
mechanistic connection was found between the lack of UBE3A
expression, interaction with clock genes, and changes in sleep–wake
cycle (Ehlen et al., 2015; Salminen, Crespi, & Mokkonen, 2019; Shi,
Bichell, Ihrie, & Johnson, 2015). Behavioral treatment on the other
hand can have a positive effect on sleep problems in AS (Allen, Kuhn,
DeHaai, & Wallace, 2013). Sleep problems in children (frequent wak-
ening and if not primarily intended co-sleeping) usually result in sleep
problems for parents as well; parents rate sleep problems as one of
their most serious concerns (Grieco, Romero, Flood, Cabo, &
Visootsak, 2019; Wheeler, Sacco, & Cabo, 2017).
4.5 | Growth and other health issues
Disproportionate growth of the head circumference, usually leading
to microcephaly (≤−2 SDS) at the age of 2 years and older is part of
the B category clinical criteria for AS, which implicates a prevalence of
>80% in AS (Williams et al., 2006). Although in our cohort the mean
head circumference was below average, with a lower mean in the
deletion group, microcephaly was seen in only 24% of all children of
2 years and older and in only five children in the nondeletion group. In
previous studies the prevalence of microcephaly varied between
38 and 80% (Mertz, Christensen, et al., 2014; Tan et al., 2011). Our
findings and those of the Danish study indicate that microcephaly
could be shifted from the B to the C category of AS diagnostic criteria
and that absence of microcephaly should not lead to rejection of a
clinical suspicion of AS, especially not of the nondeletion type.
Being overweight and obesity had a, respectively, 1.5- and 7-fold
higher occurrence in our AS cohort compared to healthy children in the
Netherlands (prevalence of 10.5 and 2.8%, respectively [Statistics Neth-
erlands' database (Centraal Bureau voor de Statistiek), n.d.]. This finding
was significantly higher in the nondeletion children, as was reported
earlier [Brennan et al., 2015; Mertz, Christensen, et al., 2014; Tan et al.,
2011]), but the mean weight for height in all genetic subtypes was
above 0 SDS. As far as we know, this is a new finding. There was also a
difference within the nondeletion group, with UPD and IC children
taken together having a nominal significantly higher weight for height
than the children with a pathogenic variant of the UBE3A gene. A simi-
lar trend was reported in a previous study of, respectively, 24 and
16 nondeletion children (Brennan et al., 2015; Tan et al., 2011), which
was attributed to the increased expression levels of paternally
expressed genes within the 15q11-13 locus. However, children with
Prader-Willi syndrome (PWS) also show obesity and carry a maternal
UPD at the same locus (Brennan et al., 2015; Mertz, Christensen, et al.,
2014). Moreover, also children with a pathogenic variant of the UBE3A
gene show a higher weight for height than deletion and non-AS chil-
dren. This has also been observed in Ube3a-mouse mutants, which was
shown to be correlated with neuronal CAMK2 activity (van Woerden
et al., 2007). Hence, further research is needed to understand the
mechanisms leading to weight gain in patients with mutations at the
15q11-13 locus. Regardless of the molecular mechanism, the metabolic
resting expenditure (REE) could be lower in AS, as is seen in PWS
(Alsaif et al., 2017). To date, no endocrine studies, skeletal bone age
evaluation, nor REE assessments have been published to gain better
understanding of growth and metabolism in AS.
One-third of our cohort showed hyperphagia as was reported previ-
ously in children with AS (Barry, Leitner, Clarke, & Einfeld, 2005; Mertz,
Christensen, et al., 2014; Salminen et al., 2019; Welham et al., 2015; Wil-
liams et al., 2006). In the Danish cohort children with UPD showed sig-
nificantly more hyperphagia, leading the authors to the hypothesis of a
role for paternal gene overexpression, as discussed with the higher
weight association (Mertz, Christensen, et al., 2014). However, we
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identified hyperphagic behavior in all genetic subtypes with no effect of
genotype. This discrepancy in findings might be due to the small number
of children with UPD and pathogenic variant of the UBE3A gene (n = 9)
and the absence of children with IC in the Danish study compared to size
(n = 38) of our nondeletion group (including four children with IC).
The somewhat lower mean height is difficult to interpret, as
parental height data were partly missing. Genotype differences were
not found, in contrast to previous studies, but information about tar-
get height was lacking in these studies as well (Mertz, Christensen,
et al., 2014; Tan et al., 2011).
Only a small number (13%) of our children needed tube feeding
and nearly all of them carried a deletion. This rate and genotype asso-
ciation is similar to a recent study from the Boston group (Glassman
et al., 2017). More severe oral motor problems and general hypotonia
probably play a role in this genotype difference. The occurrence of
GER, constipation, and scoliosis was comparable to previous reports
(Glassman et al., 2017; Sachdeva, Donkers, & Kim, 2016).
4.6 | Strengths and limitations
An important strength of this study is that, to our knowledge, it pre-
sents the largest clinical AS cohort, with prospectively collecting infor-
mation of both health issues and development. This cohort represents
approximately 75% of all children with AS in the Netherlands, which
limits referral bias. Most issues regarding health and development
(epilepsy, sleep, gastrointestinal problems, mobility, cognition, commu-
nication, and behavior) that are addressed in our clinical follow-up
were recently stated as being very important concerns for parents of
children with AS (Grieco et al., 2019; Wheeler et al., 2017) and will be
targeted as relevant clinical outcomes in future trials.
Limitations of this study are that children had different ages at
referral. Some information like achieved milestones from before referral
had to be collected retrospectively with risk of recall bias. The average
age of the first visit is much lower currently due to referral immediately
after diagnosis, which enables us to register data in greater detail and
also study age effects in the future. We had some missing data in our
standardized routine data, which reduced the power for certain ana-
lyses and may have led to an under- or overestimation of associations.
We were not able to analyze possible differences within the deletion
group based on deletion size. Previous studies (Gentile et al., 2010;
Mertz, Thaulov, et al., 2014) have not shown differences between Class
I and II with respect to development, but it would be interesting to
repeat these analyses in a larger sample size. A final limitation is the
small group of IC patients (n = 4). In order to have sufficient statistical
power, we grouped them with the children with a UPD and a patho-
genic variant of the UBE3A gene. It would be of great interest to inves-
tigate larger numbers of these subgroups in the future.
5 | CONCLUSION
Overall, the global phenotype of these 100 AS children is in line with
previous studies including the more severe phenotype in the
15q11.2-q13 deletion subtype. Novel findings in our cohort are the
association of (early onset of) epilepsy with a less favorable outcome
regarding motor, cognitive, and receptive language development. Pos-
sibly, early epilepsy treatment may improve outcome. Furthermore,
we found a not previously reported high rate of crouch gait in the
older children with a risk of deterioration of mobility, a relatively low
occurrence of microcephaly, a higher mean weight for height in all
genetic subtypes with a significant higher mean in the nondeletion
children, and a high occurrence of hyperphagia in all genetic subtypes.
In general, only limited data are available regarding underlying
mechanisms of epilepsy, sleep problems, development delay, gait
problems, hyperphagia, and growth, needing further translational
research to seek for better understanding and intervention possibili-
ties. With this large clinical cohort with structured prospective and
multidisciplinary follow-up, our ENCORE Expertise Center for AS has
the baseline data available to evaluate the effect of potential treat-
ment modalities on relevant clinical outcomes.
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